Novartis announced a new post-hoc analysis of the phase 3 heart failure study, Paradigm-HF, which demonstrated treatment with Entresto helped to preserve kidney function, as assessed by estimated glomerular filtration rate, in patients with heart failure with reduced ejection fraction. The findings of the analysis are published in The Lancet Diabetes & Endocrinology.
According to a company press release, the analysis showed patients with heart failure with reduced ejection fraction (HFrEF) treated with Entresto (sacubitril/valsartan, Novartis), a twice-a-day medicine that reduced the strain on the failing heart, had a slower rate of decline in estimated glomerular filtration rate (eGFR) than those treated with angiotensin-converting enzyme inhibitor enalapril. In a subgroup of patients who had HFrEF and diabetes, the magnitude of benefit was twice as high.
“These results suggest that in addition to the established benefits on heart failure, Entresto treatment also helps to preserve kidney function. This is important because impaired kidney function is associated with poorer outcomes in patients with heart failure,” Shreeram Aradhye, chief medical officer and global head of medical affairs for Novartis Pharmaceuticals, said in the release. “The benefit is particularly significant for people with chronic heart failure who also have diabetes, which is an independent risk factor for kidney damage.”
According to the release, patients with HFrEF but without diabetes lost kidney function twice as fast as the general population. This was further accelerated in patients with HFrEF and diabetes, who experienced a decline in kidney function that was twice as fast as patients without diabetes.
Compared with enalapril, treatment with sacubitril/valsartan significantly slowed this decline for all patients with HFrEF. In patients with HFrEF who had diabetes, the benefit of treatment with sacubitril/valsartan was doubled vs. those without diabetes.